Clinical Trial Update: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) [Phase 2]

View source ↗

Summary

A Phase 2 pharmacodynamics pre-surgical study of the CDK4/6 inhibitor ribociclib (LEE011) in patients with early breast cancer (MONALEESA-1) was terminated, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• LEE011 (ribociclib) (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Early Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-01-01